KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Notes Payables (2019 - 2025)

Biogen has reported Notes Payables over the past 12 years, most recently at $6.3 billion for Q3 2025.

  • For Q3 2025, Notes Payables rose 259.54% year-over-year to $6.3 billion; the TTM value through Sep 2025 reached $6.3 billion, up 259.54%, while the annual FY2024 figure was $1.7 billion, 74.8% down from the prior year.
  • Notes Payables for Q3 2025 was $6.3 billion at Biogen, up from $1.7 billion in the prior quarter.
  • Over five years, Notes Payables peaked at $7.3 billion in Q2 2022 and troughed at $250.0 million in Q1 2024.
  • A 5-year average of $4.2 billion and a median of $6.3 billion in 2022 define the central range for Notes Payables.
  • Biggest five-year swings in Notes Payables: crashed 74.8% in 2024 and later skyrocketed 599.64% in 2025.
  • Year by year, Notes Payables stood at $999.1 million in 2021, then skyrocketed by 528.67% to $6.3 billion in 2022, then increased by 10.46% to $6.9 billion in 2023, then crashed by 74.8% to $1.7 billion in 2024, then skyrocketed by 259.44% to $6.3 billion in 2025.
  • Business Quant data shows Notes Payables for BIIB at $6.3 billion in Q3 2025, $1.7 billion in Q1 2025, and $1.7 billion in Q4 2024.